ertugliflozin and metformin hydrochloride

FDA Drug Profile — SEGLUROMET

ertugliflozin and metformin hydrochloride is listed in the FDA National Drug Code directory with 12 NDC codes, marketed under brand name including SEGLUROMET. Available dosage form: tablet, film coated.

Drug details

Generic Name
ertugliflozin and metformin hydrochloride
Brand Names
SEGLUROMET
Application Number
NDA209806
Sponsor
MSD International GmbH (Puerto Rico Branch) LLC
NDC Codes
12
Dosage Forms
TABLET, FILM COATED
Routes
ORAL
Active Ingredients
ERTUGLIFLOZIN PIDOLATE, METFORMIN HYDROCHLORIDE

Indications and Usage

1 INDICATIONS AND USAGE SEGLUROMET ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. SEGLUROMET is a combination of ertugliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, and metformin, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use: Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. ( 1 ) Limitations of Use Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions (5.2) ].

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.